Comprehensive genomic profiling (CGP)
PanCancerIQ™ targeted panel for solid tumors. Detects SNVs/indels, CNVs, RNA fusions, and reports MSI and TMB. Available for FFPE and ctDNA.
Sequencing assays
Sequencing designed for diverse study needs
We offer a comprehensive range of sequencing capabilities to support oncology research and clinical trials, from targeted panels to broader genomic and transcriptomic approaches, delivering high‑quality data across diverse study needs.
Actionable insights from exploration to validation
We design, validate, and perform NGS assays with robust bioinformatics to support clinical trials.
Bioinformatics that scales
Our Center of Excellence for Bioinformatics & AI processes WES, RNA‑Seq, ctDNA/cfDNA, and WGBS data with cloud‑enabled pipelines—delivering variant calling, viral variant reporting to DAVP conventions, and multi‑omics analytics.
Where sequencing fits in your program
-
Oncology – patient stratification, biomarker‑driven trial optimization, and monitoring via CGP and liquid biopsy workflows.
-
Cell therapy & Gene therapy - NGS for gene signatures, transgene assessment, and biosurveillance alongside qPCR/dPCR assays.
-
Infectious Disease – variant tracking and resistance assessments in clinical studies.
Matrices & sample types
Selected to meet endpoint and stability requirements.
-
FFPE tissue
-
Whole blood/plasma (ctDNA)
-
Saliva
-
Buccal swab
-
Nasal swab
-
Other validated study matrices
Why Eurofins BioPharma Services
-
Clinical‑grade quality systems with expanding regulated capabilities and purpose‑built infrastructure for complex programs.
-
Breadth of platforms—NGS (Illumina), WES, RNA‑Seq, Sanger, plus NanoString for orthogonal expression analysis.
-
Custom assay development—fit‑for‑purpose designs, validation, and transfer for your targets and endpoints.
Start your sequencing plan
